447 related articles for article (PubMed ID: 29669936)
1. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
Jin BY; Campbell TE; Draper LM; Stevanović S; Weissbrich B; Yu Z; Restifo NP; Rosenberg SA; Trimble CL; Hinrichs CS
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669936
[TBL] [Abstract][Full Text] [Related]
2. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
4. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
Draper LM; Kwong ML; Gros A; Stevanović S; Tran E; Kerkar S; Raffeld M; Rosenberg SA; Hinrichs CS
Clin Cancer Res; 2015 Oct; 21(19):4431-9. PubMed ID: 26429982
[TBL] [Abstract][Full Text] [Related]
5. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
Jiang B; Xue M
Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women.
Papasavvas E; Kossenkov AV; Azzoni L; Zetola NM; Mackiewicz A; Ross BN; Fair M; Vadrevu S; Ramogola-Masire D; Sanne I; Firnhaber C; Montaner LJ
Carcinogenesis; 2019 Apr; 40(2):225-233. PubMed ID: 30364933
[TBL] [Abstract][Full Text] [Related]
7. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene.
Jabbar SF; Abrams L; Glick A; Lambert PF
Cancer Res; 2009 May; 69(10):4407-14. PubMed ID: 19435895
[TBL] [Abstract][Full Text] [Related]
8. Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV
Galliverti G; Wullschleger S; Tichet M; Murugan D; Zangger N; Horton W; Korman AJ; Coussens LM; Swartz MA; Hanahan D
Cancer Immunol Res; 2020 Jan; 8(1):131-145. PubMed ID: 31771984
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
Passmore JA; Milner M; Denny L; Sampson C; Marais DJ; Allan B; Gumbi PP; Hitzeroth II; Rybicki EP; Williamson AL
Immunology; 2006 Dec; 119(4):507-14. PubMed ID: 17026720
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.
Woodworth CD; Diefendorf LP; Jette DF; Mohammed A; Moses MA; Searleman SA; Stevens DA; Wilton KM; Mondal S
Virology; 2011 Dec; 421(1):19-27. PubMed ID: 21982220
[TBL] [Abstract][Full Text] [Related]
11. High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies.
Fiedler M; Müller-Holzner E; Viertler HP; Widschwendter A; Laich A; Pfister G; Spoden GA; Jansen-Dürr P; Zwerschke W
FASEB J; 2004 Jul; 18(10):1120-2. PubMed ID: 15155561
[TBL] [Abstract][Full Text] [Related]
12. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri.
Melsheimer P; Vinokurova S; Wentzensen N; Bastert G; von Knebel Doeberitz M
Clin Cancer Res; 2004 May; 10(9):3059-63. PubMed ID: 15131043
[TBL] [Abstract][Full Text] [Related]
13. The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma.
Li W; Wang W; Si M; Han L; Gao Q; Luo A; Li Y; Lu Y; Wang S; Ma D
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1355-61. PubMed ID: 18478264
[TBL] [Abstract][Full Text] [Related]
14. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
15. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
Cheng WF; Lee CN; Su YN; Chang MC; Hsiao WC; Chen CA; Hsieh CY
Immunology; 2005 May; 115(1):136-49. PubMed ID: 15819706
[TBL] [Abstract][Full Text] [Related]
16. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML
Lancet; 2015 Nov; 386(10008):2078-2088. PubMed ID: 26386540
[TBL] [Abstract][Full Text] [Related]
17. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
[TBL] [Abstract][Full Text] [Related]
19. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
20. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
Zeng Q; Peng S; Monie A; Yang M; Pang X; Hung CF; Wu TC
Hum Gene Ther; 2011 Jul; 22(7):809-19. PubMed ID: 21128743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
